Navigation Links
Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
Date:4/24/2013

about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact
Beatrice Hirt
Communication Coordinator
bhirt@debiopharm.com
Tel.: +41-21-321-01-11

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf , Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com

Oncotest GmbH Contact
Dr. Ingmar Peitz
Business Development
Ingmar.Peitz@Oncotest.de
Tel.: +49(0)761-51559-42



'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
2. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
3. The SDS/MSA Support Group Officially Changes Name to The Multiple System Atrophy Coalition
4. Many Ginkgo Extracts Safe, Says Herbal Science Group
5. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
6. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
7. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
8. Atlantica Group LLC to Support International "Soft-Landing" Efforts of Incubators and Accelerators
9. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 Eisai Co., Ltd.,(Headquarters: Tokyo, President & ... of North America (Headquarters: New Jersey,the United States, ... in the schedule for submission to the U.S. ... Application (NDA) for E7389 (generic,name: eribulin mesylate) for ...
... 1 , - ENDORSE Global Findings Highlight ... VTE Management: Systematically Assess,Patient Risk for VTE and ... multinational study (Epidemiologic International Day for the,Evaluation of ... Acute,Hospital Care Setting) published today in the LANCET(1) ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced that ... community in New York City on Thursday, February 7,2008 ... be webcast live and available for replay on the,company,s ... CV Therapeutics, Inc., headquartered in Palo Alto, California, ...
Cached Biology Technology:Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 2Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 2The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 4CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... our cells migrate: nerve cells make their vital connections, ... organs, immune cells zero in to destroy pathogenic organisms, ... body. Scientists studying these migrations didn't know how cells ... Institute study has identified a fragment of a protein ...
... does matters after all. But for flying snakes, smaller ... In the May 15, 2005, issue of the Journal ... and behavior of flying snakes, and found that the ... of wing-like appendages, flying snakes are skilled aerial locomotors," ...
... Virginia Tech, has been awarded a Ralph E. Powe Junior ... his research on quorum sensing in bacteria. He is modeling ... by a bacteria colony once it has reached a critical ... to faculty members who are in the first two years ...
Cached Biology News:New understanding of cell movement may yield ways to brake cancer's spread 2Researchers reveal secrets of flying snakes 2Researchers reveal secrets of flying snakes 3Understanding how bacteria communicate may help scientists prevent disease 2Understanding how bacteria communicate may help scientists prevent disease 3
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Biology Products: